Professional Writing

Bibliography: Peer-reviewed manuscripts

1. Seibyl JP, Kuo P. What Is the Role of Dopamine Transporter Imaging in Parkinson Prevention Clinical Trials? Neurology. 2022;99(7 Suppl 1):61-7.

2. Seibyl JP, DuBois JM, Racine A, Collins J, Guo Q, Wooten D, et al. A Visual Interpretation Algorithm for Assessing Brain Tauopathy with 18-F MK-6240 Positron Emission Tomography. J Nucl Med. 2022.

3. Seibyl JP. Alpha-synuclein PET and Parkinson's Disease Therapeutic Trials: Ever the Twain Shall Meet? J Nucl Med. 2022.

4. Seibyl J. Imaging Biomarkers for CNS Drug Development and Future Clinical Utility: Lessons from Neurodegenerative Disorders. J Nucl Med. 2022.

5. Messerschmidt K, Barthel H, Brendel M, Scherlach C, Hoffmann KT, Rauchmann BS, et al. (18)F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy. J Nucl Med. 2022.

6. Macklin EA, Coffey CS, Brumm MC, Seibyl JP. Statistical Considerations in the Design of Clinical Trials Targeting Prodromal Parkinson Disease. Neurology. 2022;99(7 Suppl 1):68-75.

7. Koike T, Constantinescu CC, Ikeda S, Nishi T, Sunahara E, Miyamoto M, et al. Preclinical characterization of [(18)F]T-008, a novel PET imaging radioligand for cholesterol 24-hydroxylase. Eur J Nucl Med Mol Imaging. 2022;49(4):1148-56.

8. Katzdobler S, Nitschmann A, Barthel H, Bischof G, Beyer L, Marek K, et al. Additive value of [(18)F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome. Eur J Nucl Med Mol Imaging. 2022.

9. Franzmeier N, Brendel M, Beyer L, Slemann L, Kovacs GG, Arzberger T, et al. Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nat Commun. 2022;13(1):1362.

10. Brasic JR, Goodman JA, Nandi A, Russell DS, Jennings D, Barret O, et al. Fragile X Mental Retardation Protein and Cerebral Expression of Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome: A Pilot Study. Brain Sci. 2022;12(3).

11. Song M, Scheifele M, Barthel H, van Eimeren T, Beyer L, Marek K, et al. Feasibility of short imaging protocols for [(18)F]PI-2620 tau-PET in progressive supranuclear palsy. Eur J Nucl Med Mol Imaging. 2021;48(12):3872-85.

12. Song M, Beyer L, Kaiser L, Barthel H, van Eimeren T, Marek K, et al. Binding characteristics of [(18)F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. J Cereb Blood Flow Metab. 2021;41(11):2957-72.

13. Kremer T, Taylor KI, Siebourg-Polster J, Gerken T, Staempfli A, Czech C, et al. Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease. Mov Disord. 2021;36(8):1972-8.

14. Concha-Marambio L, Farris CM, Holguin B, Ma Y, Seibyl J, Russo MJ, et al. Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression. Mov Disord. 2021;36(10):2444-6.

15. Bullich S, Roe-Vellve N, Marquie M, Landau SM, Barthel H, Villemagne VL, et al. Early detection of amyloid load using (18)F-florbetaben PET. Alzheimers Res Ther. 2021;13(1):67.

16. Brasic JR, Nandi A, Russell DS, Jennings D, Barret O, Martin SD, et al. Cerebral Expression of Metabotropic Glutamate Receptor Subtype 5 in Idiopathic Autism Spectrum Disorder and Fragile X Syndrome: A Pilot Study. Int J Mol Sci. 2021;22(6).

17. Bischof GN, Bartenstein P, Barthel H, van Berckel B, Dore V, van Eimeren T, et al. Toward a Universal Readout for (18)F-Labeled Amyloid Tracers: The CAPTAINs Study. J Nucl Med. 2021;62(7):999-1005.

18. Barret O, Zhang L, Alagille D, Constantinescu CC, Sandiego C, Papin C, et al. Dopamine D1 Receptor Agonist PET Tracer Development: Assessment in Nonhuman Primates. J Nucl Med. 2021;62(9):1307-13.

19. Simuni T, Uribe L, Cho HR, Caspell-Garcia C, Coffey CS, Siderowf A, et al. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. Lancet Neurol. 2020;19(1):71-80.

20. Simuni T, Brumm MC, Uribe L, Caspell-Garcia C, Coffey CS, Siderowf A, et al. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study. Mov Disord. 2020;35(5):833-44.

21. Siderowf A, Jennings D, Stern M, Seibyl J, Eberly S, Oakes D, et al. Clinical and Imaging Progression in the PARS Cohort: Long-Term Follow-up. Mov Disord. 2020;35(9):1550-7.

22. Mueller A, Bullich S, Barret O, Madonia J, Berndt M, Papin C, et al. Tau PET imaging with (18)F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study. J Nucl Med. 2020;61(6):911-9.

23. Morbelli S, Esposito G, Arbizu J, Barthel H, Boellaard R, Bohnen NI, et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging. 2020;47(8):1885-912.

24. Mollenhauer B, Dakna M, Kruse N, Galasko D, Foroud T, Zetterberg H, et al. Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression. Mov Disord. 2020;35(11):1999-2008.

25. Bullich S, Barret O, Constantinescu C, Sandiego C, Mueller A, Berndt M, et al. Evaluation of Dosimetry, Quantitative Methods, and Test-Retest Variability of (18)F-PI-2620 PET for the Assessment of Tau Deposits in the Human Brain. J Nucl Med. 2020;61(6):920-7.

26. Brendel M, Barthel H, van Eimeren T, Marek K, Beyer L, Song M, et al. Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurol. 2020;77(11):1408-19.

27. Brasic JR, Nandi A, Russell DS, Jennings D, Barret O, Mathur A, et al. Reduced Expression of Cerebral Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome. Brain Sci. 2020;10(12).

28. Beyer L, Nitschmann A, Barthel H, van Eimeren T, Unterrainer M, Sauerbeck J, et al. Early-phase [(18)F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. Eur J Nucl Med Mol Imaging. 2020;47(12):2911-22.

29. Beyer L, Brendel M, Scheiwein F, Sauerbeck J, Hosakawa C, Alberts I, et al. Improved Risk Stratification for Progression from Mild Cognitive Impairment to Alzheimer's Disease with a Multi-Analytical Evaluation of Amyloid-beta Positron Emission Tomography. J Alzheimers Dis. 2020;74(1):101-12.

30. Barthel H, Seibyl J, Lammertsma AA, Villemagne VL, Sabri O. Exploiting the Full Potential of beta-Amyloid and Tau PET Imaging for Drug Efficacy Testing. J Nucl Med. 2020;61(8):1105-6.

31. Stephenson D, Hill D, Cedarbaum JM, Tome M, Vamvakas S, Romero K, et al. The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease. J Parkinsons Dis. 2019;9(4):825.

32. Sandiego CM, Barret O, Lee H, Alagille D, Amenta A, Fowles K, et al. Imaging histamine H3 receptors with [(18) F]FMH3: Test-retest and occupancy studies in the non-human primate. Synapse. 2019;73(7):e22096.

33. Sanabria Bohorquez S, Marik J, Ogasawara A, Tinianow JN, Gill HS, Barret O, et al. [(18)F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2019;46(10):2077-89.

34. Romero K, Conrado D, Burton J, Nicholas T, Sinha V, Macha S, et al. Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's Disease. Clin Transl Sci. 2019;12(3):240-6.

35. Mollenhauer B, Caspell-Garcia CJ, Coffey CS, Taylor P, Singleton A, Shaw LM, et al. Longitudinal analyses of cerebrospinal fluid alpha-Synuclein in prodromal and early Parkinson's disease. Mov Disord. 2019;34(9):1354-64.

36. Constantinescu CC, Tresse C, Zheng M, Gouasmat A, Carroll VM, Mistico L, et al. Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers. Mol Imaging Biol. 2019;21(3):509-18.

37. Chu Y, Muller S, Tavares A, Barret O, Alagille D, Seibyl J, et al. Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes. Brain. 2019;142(11):3565-79.

38. Wilcock GK, Gauthier S, Frisoni GB, Jia J, Hardlund JH, Moebius HJ, et al. Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. J Alzheimers Dis. 2018;61(1):435-57.

39. Wang H, Atik A, Stewart T, Ginghina C, Aro P, Kerr KF, et al. Plasma alpha-synuclein and cognitive impairment in the Parkinson's Associated Risk Syndrome: A pilot study. Neurobiol Dis. 2018;116:53-9.

40. Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, et al. Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort. Mov Disord. 2018;33(5):771-82.

41. Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, et al. The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. Ann Clin Transl Neurol. 2018;5(12):1460-77.

42. Lundeen TF, Seibyl JP, Covington MF, Eshghi N, Kuo PH. Signs and Artifacts in Amyloid PET. Radiographics. 2018;38(7):2123-33.

43. Koros C, Simitsi A, Prentakis A, Beratis I, Papadimitriou D, Kontaxopoulou D, et al. 123I-FP-CIT SPECT [(123) I-2beta-carbomethoxy-3beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T alpha-synuclein Parkinson's disease cohort versus Parkinson's disease. Mov Disord. 2018;33(11):1734-9.

44. Ketcherside A, Filbey FM, Aubert PM, Seibyl JP, Price JL, Adinoff B. Brain intrinsic network connectivity in individuals with frequent tanning behavior. Am J Drug Alcohol Abuse. 2018;44(6):668-77.

45. Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, et al. CSF biomarkers of Alzheimer's disease concord with amyloid-beta PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14(11):1470-81.

46. Devous MD, Sr., Joshi AD, Navitsky M, Southekal S, Pontecorvo MJ, Shen H, et al. Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18. J Nucl Med. 2018;59(6):937-43.

47. Chahine LM, Beach TG, Seedorff N, Caspell-Garcia C, Coffey CS, Brumm M, et al. Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for alpha-Synuclein in Parkinson's Disease: The Systemic Synuclein Sampling Study (S4). J Parkinsons Dis. 2018;8(4):517-27.

48. Beach TG, Serrano GE, Kremer T, Canamero M, Dziadek S, Sade H, et al. Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4). J Neuropathol Exp Neurol. 2018;77(9):793-802.

49. Weintraub D, Chahine LM, Hawkins KA, Siderowf A, Eberly S, Oakes D, et al. Cognition and the course of prodromal Parkinson's disease. Mov Disord. 2017;32(11):1640-5.

50. Schipke CG, Koglin N, Bullich S, Joachim LK, Haas B, Seibyl J, et al. Correlation of florbetaben PET imaging and the amyloid peptide Ass42 in cerebrospinal fluid. Psychiatry Res Neuroimaging. 2017;265:98-101.

51. Sabbagh MN, Schauble B, Anand K, Richards D, Murayama S, Akatsu H, et al. Histopathology and Florbetaben PET in Patients Incorrectly Diagnosed with Alzheimer's Disease. J Alzheimers Dis. 2017;56(2):441-6.

52. Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, et al. Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort. JAMA Neurol. 2017;74(8):933-40.

53. Isaacson SH, Fisher S, Gupta F, Hermanowicz N, Kremens DE, Lew MF, et al. Clinical utility of DaTscan imaging in the evaluation of patients with parkinsonism: a US perspective. Expert Rev Neurother. 2017;17(3):219-25.

54. Fleisher AS, Joshi AD, Sundell KL, Chen YF, Kollack-Walker S, Lu M, et al. Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials. Alzheimers Dement. 2017;13(10):1117-24.

55. Bullich S, Seibyl J, Catafau AM, Jovalekic A, Koglin N, Barthel H, et al. Optimized classification of (18)F-Florbetaben PET scans as positive and negative using an SUVR quantitative approach and comparison to visual assessment. Neuroimage Clin. 2017;15:325-32.

56. Blautzik J, Brendel M, Sauerbeck J, Kotz S, Scheiwein F, Bartenstein P, et al. Reference region selection and the association between the rate of amyloid accumulation over time and the baseline amyloid burden. Eur J Nucl Med Mol Imaging. 2017;44(8):1364-74.

57. Barthel H, Seibyl J, Sabri O. Yes we can analyse amyloid images - Now What? Eur J Nucl Med Mol Imaging. 2017;44(5):822-4.

58. Barret O, Alagille D, Sanabria S, Comley RA, Weimer RM, Borroni E, et al. Kinetic Modeling of the Tau PET Tracer (18)F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects. J Nucl Med. 2017;58(7):1124-31.

59. Seibyl J, Catafau AM, Barthel H, Ishii K, Rowe CC, Leverenz JB, et al. Impact of Training Method on the Robustness of the Visual Assessment of 18F-Florbetaben PET Scans: Results from a Phase-3 Study. J Nucl Med. 2016;57(6):900-6.

60. Russell DS, Jennings DL, Barret O, Tamagnan GD, Carroll VM, Caille F, et al. Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging. Neurology. 2016;86(8):748-54.

61. Rullmann M, Dukart J, Hoffmann KT, Luthardt J, Tiepolt S, Patt M, et al. Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben beta-Amyloid PET Scans. J Nucl Med. 2016;57(2):198-203.

62. Minoshima S, Drzezga AE, Barthel H, Bohnen N, Djekidel M, Lewis DH, et al. SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0. J Nucl Med. 2016;57(8):1316-22.

63. Maya Y, Okumura Y, Kobayashi R, Onishi T, Shoyama Y, Barret O, et al. Preclinical properties and human in vivo assessment of 123I-ABC577 as a novel SPECT agent for imaging amyloid-beta. Brain. 2016;139(Pt 1):193-203.

64. Hankir MK, Kranz M, Gnad T, Weiner J, Wagner S, Deuther-Conrad W, et al. A novel thermoregulatory role for PDE10A in mouse and human adipocytes. EMBO Mol Med. 2016;8(7):796-812.

65. Chahine LM, Weintraub D, Hawkins KA, Siderowf A, Eberly S, Oakes D, et al. Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings. Mov Disord. 2016;31(1):86-94.

66. Catafau AM, Bullich S, Seibyl JP, Barthel H, Ghetti B, Leverenz J, et al. Cerebellar Amyloid-beta Plaques: How Frequent Are They, and Do They Influence 18F-Florbetaben SUV Ratios? J Nucl Med. 2016;57(11):1740-5.

67. Aubert PM, Seibyl JP, Price JL, Harris TS, Filbey FM, Jacobe H, et al. Dopamine efflux in response to ultraviolet radiation in addicted sunbed users. Psychiatry Res Neuroimaging. 2016;251:7-14.

68. Zhang Y, Wu IW, Buckley S, Coffey CS, Foster E, Mendick S, et al. Diffusion tensor imaging of the nigrostriatal fibers in Parkinson's disease. Mov Disord. 2015;30(9):1229-36.

69. Schuff N, Wu IW, Buckley S, Foster ED, Coffey CS, Gitelman DR, et al. Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits. Mov Disord. 2015;30(14):1885-92.

70. Sabri O, Seibyl J, Rowe C, Barthel H. Beta-amyloid imaging with florbetaben. Clin Transl Imaging. 2015;3(1):13-26.

71. Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. Alzheimers Dement. 2015;11(8):964-74.

72. Qamhawi Z, Towey D, Shah B, Pagano G, Seibyl J, Marek K, et al. Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease. Brain. 2015;138(Pt 10):2964-73.

73. Ong KT, Villemagne VL, Bahar-Fuchs A, Lamb F, Langdon N, Catafau AM, et al. Abeta imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study. J Neurol Neurosurg Psychiatry. 2015;86(4):431-6.

74. Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, et al. Author Response. Neurology. 2015;84(22):2292.

75. Jennings D, Seibyl J, Sabbagh M, Lai F, Hopkins W, Bullich S, et al. Age dependence of brain beta-amyloid deposition in Down syndrome: An [18F]florbetaben PET study. Neurology. 2015;84(5):500-7.

76. Covington MF, Seibyl J, Kuo PH. Adjusting ACR Appropriateness Criteria for Novel Radiopharmaceuticals. J Am Coll Radiol. 2015;12(12 Pt A):1242-3.

77. Coric V, Salloway S, van Dyck CH, Dubois B, Andreasen N, Brody M, et al. Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial. JAMA Neurol. 2015;72(11):1324-33.

78. Brendel M, Hogenauer M, Delker A, Sauerbeck J, Bartenstein P, Seibyl J, et al. Improved longitudinal [(18)F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction. Neuroimage. 2015;108:450-9.

79. Barthel H, Seibyl J, Sabri O. The role of positron emission tomography imaging in understanding Alzheimer's disease. Expert Rev Neurother. 2015;15(4):395-406.

80. Barret O, Hannestad J, Vala C, Alagille D, Tavares A, Laruelle M, et al. Characterization in humans of 18F-MNI-444, a PET radiotracer for brain adenosine 2A receptors. J Nucl Med. 2015;56(4):586-91.

81. Tavares AA, Caille F, Barret O, Papin C, Lee H, Morley TJ, et al. Whole-body biodistribution and dosimetry estimates of a novel radiotracer for imaging of serotonin 4 receptors in brain: [(1)(8)F]MNI-698. Nucl Med Biol. 2014;41(5):432-9.

82. Tavares AA, Caille F, Barret O, Papin C, Lee H, Morley TJ, et al. In vivo evaluation of 18F-MNI698: an 18F-labeled radiotracer for imaging of serotonin 4 receptors in brain. J Nucl Med. 2014;55(5):858-64.

83. Tanner CM, Meng CC, Ravina B, Lang A, Kurlan R, Marek K, et al. A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study. Mov Disord. 2014;29(6):743-9.

84. Shah M, Seibyl J, Cartier A, Bhatt R, Catafau AM. Molecular imaging insights into neurodegeneration: focus on alpha-synuclein radiotracers. J Nucl Med. 2014;55(9):1397-400.

85. Seibyl JP, Kupsch A, Booij J, Grosset DG, Costa DC, Hauser RA, et al. Individual-reader diagnostic performance and between-reader agreement in assessment of subjects with Parkinsonian syndrome or dementia using 123I-ioflupane injection (DaTscan) imaging. J Nucl Med. 2014;55(8):1288-96.

86. Russell DS, Barret O, Jennings DL, Friedman JH, Tamagnan GD, Thomae D, et al. The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease. JAMA Neurol. 2014;71(12):1520-8.

87. Mitsis EM, Riggio S, Kostakoglu L, Dickstein DL, Machac J, Delman B, et al. Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathies: studies of a retired NFL player and of a man with FTD and a severe head injury. Transl Psychiatry. 2014;4:e441.

88. Marek K, Seibyl J, Eberly S, Oakes D, Shoulson I, Lang AE, et al. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology. 2014;82(20):1791-7.

89. Kuo PH, Lei HH, Avery R, Krupinski EA, Bauer A, Sherman S, et al. Evaluation of an Objective Striatal Analysis Program for Determining Laterality in Uptake of (1)(2)(3)I-Ioflupane SPECT Images: Comparison to Clinical Symptoms and to Visual Reads. J Nucl Med Technol. 2014;42(2):105-8.

90. Kessler RM, Seibyl J, Cowan RL, Zald D, Young JS, Ansari MS, et al. Radiation Dosimetry of (18)F-FPEB in Humans. J Nucl Med. 2014;55(7):1119-21.

91. Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, et al. Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study. Neurology. 2014;83(19):1739-46.

92. Jennings D, Eberly S, Oakes D, Seibyl J, Marek K, Shoulson I, et al. Impact of disclosure of individual imaging results in a multi-center Parkinson clinical trial. J Parkinsons Dis. 2014;4(4):629-38.

93. Grosset DG, Tatsch K, Oertel WH, Tolosa E, Bajaj N, Kupsch A, et al. Safety analysis of 10 clinical trials and for 13 years after first approval of ioflupane 123I injection (DaTscan). J Nucl Med. 2014;55(8):1281-7.

94. Barret O, Thomae D, Tavares A, Alagille D, Papin C, Waterhouse R, et al. In vivo assessment and dosimetry of 2 novel PDE10A PET radiotracers in humans: 18F-MNI-659 and 18F-MNI-654. J Nucl Med. 2014;55(8):1297-304.

95. Barret O, Hannestad J, Alagille D, Vala C, Tavares A, Papin C, et al. Adenosine 2A receptor occupancy by tozadenant and preladenant in rhesus monkeys. J Nucl Med. 2014;55(10):1712-8.

96. Bajaj N, Hauser RA, Seibyl J, Kupsch A, Plotkin M, Chen C, et al. Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCAN) in subjects with clinically uncertain parkinsonian syndromes. Alzheimers Res Ther. 2014;6(5-8):67.

97. Tavares AA, Batis JC, Papin C, Jennings D, Alagille D, Russell DS, et al. Kinetic modeling, test-retest, and dosimetry of 123I-MNI-420 in humans. J Nucl Med. 2013;54(10):1760-7.

98. Tavares AA, Batis J, Barret O, Alagille D, Vala C, Kudej G, et al. In vivo evaluation of [(123)I]MNI-420: a novel single photon emission computed tomography radiotracer for imaging of adenosine 2A receptors in brain. Nucl Med Biol. 2013;40(3):403-9.

99. Tavares AA, Barret O, Batis J, Alagille D, Koren A, Papin C, et al. Kinetic modeling and occupancy measures of the norepinephrine transporters in baboons using single photon emission computed tomography with (123)I-INER. Synapse. 2013;67(1):30-41.

100. Sullivan JM, Lim K, Labaree D, Lin SF, McCarthy TJ, Seibyl JP, et al. Kinetic analysis of the metabotropic glutamate subtype 5 tracer [(18)F]FPEB in bolus and bolus-plus-constant-infusion studies in humans. J Cereb Blood Flow Metab. 2013;33(4):532-41.

101. Seegal RF, Fitzgerald EF, McCaffrey RJ, Shrestha S, Hills EA, Wolff MS, et al. Tibial bone lead, but not serum polychlorinated biphenyl, concentrations are associated with neurocognitive deficits in former capacitor workers. J Occup Environ Med. 2013;55(5):552-62.

102. Kuo PH, Avery R, Krupinski E, Lei H, Bauer A, Sherman S, et al. Receiver-operating-characteristic analysis of an automated program for analyzing striatal uptake of 123I-ioflupane SPECT images: calibration using visual reads. J Nucl Med Technol. 2013;41(1):26-31.

103. Hannestad JO, Cosgrove KP, DellaGioia NF, Perkins E, Bois F, Bhagwagar Z, et al. Changes in the cholinergic system between bipolar depression and euthymia as measured with [123I]5IA single photon emission computed tomography. Biol Psychiatry. 2013;74(10):768-76.

104. Esterlis I, McKee SA, Kirk K, Lee D, Bois F, Stiklus SM, et al. Sex-specific differences in GABA(A) -benzodiazepine receptor availability: relationship with sensitivity to pain and tobacco smoking craving. Addict Biol. 2013;18(2):370-8.

105. Esterlis I, Hannestad JO, Perkins E, Bois F, D'Souza DC, Tyndale RF, et al. Effect of a nicotine vaccine on nicotine binding to beta2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers. Am J Psychiatry. 2013;170(4):399-407.

106. Esterlis I, Hannestad JO, Bois F, Sewell RA, Tyndale RF, Seibyl JP, et al. Imaging changes in synaptic acetylcholine availability in living human subjects. J Nucl Med. 2013;54(1):78-82.

107. Caille F, Morley TJ, Tavares AA, Papin C, Twardy NM, Alagille D, et al. Synthesis and biological evaluation of positron emission tomography radiotracers targeting serotonin 4 receptors in brain: [18F]MNI-698 and [18F]MNI-699. Bioorg Med Chem Lett. 2013;23(23):6243-7.

108. Tavares AA, Jobson NK, Dewar D, Sutherland A, Pimlott SL, Batis J, et al. Iodine-123 labeled reboxetine analogues for imaging of noradrenaline transporter in brain using single photon emission computed tomography. Synapse. 2012;66(11):923-30.

109. Seibyl J, Russell D, Jennings D, Marek K. The molecular basis of dopaminergic brain imaging in Parkinson's disease. Q J Nucl Med Mol Imaging. 2012;56(1):4-16.

110. Seibyl J, Russell D, Jennings D, Marek K. Neuroimaging over the course of Parkinson's disease: from early detection of the at-risk patient to improving pharmacotherapy of later-stage disease. Semin Nucl Med. 2012;42(6):406-14.

111. Saricicek A, Esterlis I, Maloney KH, Mineur YS, Ruf BM, Muralidharan A, et al. Persistent beta2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder. Am J Psychiatry. 2012;169(8):851-9.

112. Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects. J Nucl Med. 2012;53(3):378-84.

113. Djang DS, Janssen MJ, Bohnen N, Booij J, Henderson TA, Herholz K, et al. SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. J Nucl Med. 2012;53(1):154-63.

114. D'Souza DC, Esterlis I, Carbuto M, Krasenics M, Seibyl J, Bois F, et al. Lower ss2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia. Am J Psychiatry. 2012;169(3):326-34.

115. Cosgrove KP, Esterlis I, McKee SA, Bois F, Seibyl JP, Mazure CM, et al. Sex differences in availability of beta2*-nicotinic acetylcholine receptors in recently abstinent tobacco smokers. Arch Gen Psychiatry. 2012;69(4):418-27.

116. Batis J, Barret O, Alagille D, Koren AO, Stehouwer JS, Cosgrove K, et al. In vivo evaluation of [(1)(2)(3)I]mZIENT as a SPECT radioligand for the serotonin transporter. Nucl Med Biol. 2012;39(8):1137-41.

117. Seibyl J, Zubal IG, Jennings D, Marek K, Doraiswamy PM. Molecular PET imaging in multicenter Alzheimer's therapeutic trials: current trends and implementation strategies. Expert Rev Neurother. 2011;11(12):1783-93.

118. Seegal RF, Fitzgerald EF, Hills EA, Wolff MS, Haase RF, Todd AC, et al. Estimating the half-lives of PCB congeners in former capacitor workers measured over a 28-year interval. J Expo Sci Environ Epidemiol. 2011;21(3):234-46.

119. Schwarzschild MA, Marek K, Eberly S, Oakes D, Shoulson I, Jennings D, et al. Serum urate and probability of dopaminergic deficit in early "Parkinson's disease". Mov Disord. 2011;26(10):1864-8.

120. Esterlis I, Mitsis EM, Batis JC, Bois F, Picciotto MR, Stiklus SM, et al. Brain beta2*-nicotinic acetylcholine receptor occupancy after use of a nicotine inhaler. Int J Neuropsychopharmacol. 2011;14(3):389-98.

121. Chin CL, Carr RA, Llano DA, Barret O, Xu H, Batis J, et al. Pharmacokinetic modeling and [(1)(2)(3)]5-IA-85380 single photon emission computed tomography imaging in baboons: optimization of dosing regimen for ABT-089. J Pharmacol Exp Ther. 2011;336(3):716-23.

122. Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10(5):424-35.

123. Ahn K, Gil R, Seibyl J, Sewell RA, D'Souza DC. Probing GABA receptor function in schizophrenia with iomazenil. Neuropsychopharmacology. 2011;36(3):677-83.

124. Sewell RA, Perry EB, Jr., Karper LP, Bell MD, Lysaker P, Goulet JL, et al. Clinical significance of neurological soft signs in schizophrenia: factor analysis of the Neurological Evaluation Scale. Schizophr Res. 2010;124(1-3):1-12.

125. Seibyl JP. SPECT and PET in Atypical Parkinsonism. PET Clin. 2010;5(1):65-74.

126. Seibyl J, Marek K, Zubal IG. The role of the core imaging laboratory in multicenter trials. Semin Nucl Med. 2010;40(5):338-46.

127. Seegal RF, Marek KL, Seibyl JP, Jennings DL, Molho ES, Higgins DS, et al. Occupational exposure to PCBs reduces striatal dopamine transporter densities only in women: a beta-CIT imaging study. Neurobiol Dis. 2010;38(2):219-25.

128. Hall DA, Jennings D, Seibyl J, Tassone F, Marek K. FMR1 gene expansion and scans without evidence of dopaminergic deficits in parkinsonism patients. Parkinsonism Relat Disord. 2010;16(9):608-11.

129. Esterlis I, Cosgrove KP, Petrakis IL, McKee SA, Bois F, Krantzler E, et al. SPECT imaging of nicotinic acetylcholine receptors in nonsmoking heavy alcohol drinking individuals. Drug Alcohol Depend. 2010;108(1-2):146-50.

130. Esterlis I, Cosgrove KP, Batis JC, Bois F, Stiklus SM, Perkins E, et al. Quantification of smoking-induced occupancy of beta2-nicotinic acetylcholine receptors: estimation of nondisplaceable binding. J Nucl Med. 2010;51(8):1226-33.

131. Cosgrove KP, Tellez-Jacques K, Pittman B, Petrakis I, Baldwin RM, Tamagnan G, et al. Dopamine and serotonin transporter availability in chronic heroin users: a [(1)(2)(3)I]beta-CIT SPECT imaging study. Psychiatry Res. 2010;184(3):192-5.

132. Cosgrove KP, Staley JK, Baldwin RM, Bois F, Plisson C, Al-Tikriti MS, et al. SPECT imaging with the serotonin transporter radiotracer [123I]p ZIENT in nonhuman primate brain. Nucl Med Biol. 2010;37(5):587-91.

133. Cosgrove KP, Kloczynski T, Bois F, Pittman B, Tamagnan G, Seibyl JP, et al. Decreased Beta(2)*-nicotinic acetylcholine receptor availability after chronic ethanol exposure in nonhuman primates. Synapse. 2010;64(9):729-32.

134. Cosgrove KP, Esterlis I, McKee S, Bois F, Alagille D, Tamagnan GD, et al. Beta2* nicotinic acetylcholine receptors modulate pain sensitivity in acutely abstinent tobacco smokers. Nicotine Tob Res. 2010;12(5):535-9.

135. Mitsis EM, Reech KM, Bois F, Tamagnan GD, Macavoy MG, Seibyl JP, et al. 123I-5-IA-85380 SPECT imaging of nicotinic receptors in Alzheimer disease and mild cognitive impairment. J Nucl Med. 2009;50(9):1455-63.

136. Mitsis EM, Cosgrove KP, Staley JK, Bois F, Frohlich EB, Tamagnan GD, et al. Age-related decline in nicotinic receptor availability with [(123)I]5-IA-85380 SPECT. Neurobiol Aging. 2009;30(9):1490-7.

137. Esterlis I, Cosgrove KP, Batis JC, Bois F, Kloczynski TA, Stiklus SM, et al. GABAA-benzodiazepine receptor availability in smokers and nonsmokers: relationship to subsyndromal anxiety and depression. Synapse. 2009;63(12):1089-99.

138. Cosgrove KP, Krantzler E, Frohlich EB, Stiklus S, Pittman B, Tamagnan GD, et al. Dopamine and serotonin transporter availability during acute alcohol withdrawal: effects of comorbid tobacco smoking. Neuropsychopharmacology. 2009;34(10):2218-26.

139. Cosgrove KP, Batis J, Bois F, Maciejewski PK, Esterlis I, Kloczynski T, et al. beta2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Arch Gen Psychiatry. 2009;66(6):666-76.

140. van Dyck CH, Avery RA, MacAvoy MG, Marek KL, Quinlan DM, Baldwin RM, et al. Striatal dopamine transporters correlate with simple reaction time in elderly subjects. Neurobiol Aging. 2008;29(8):1237-46.

141. Seibyl JP. Single-photon emission computed tomography and positron emission tomography evaluations of patients with central motor disorders. Semin Nucl Med. 2008;38(4):274-86.

142. Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008;65(6):716-23.

143. Marek K, Jennings D, Tamagnan G, Seibyl J. Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression. Ann Neurol. 2008;64 Suppl 2:S111-21.

144. Czermak C, Staley JK, Kasserman S, Bois F, Young T, Henry S, et al. beta2 Nicotinic acetylcholine receptor availability in post-traumatic stress disorder. Int J Neuropsychopharmacol. 2008;11(3):419-24.

145. Barret O, Mazere J, Seibyl J, Allard M. Comparison of noninvasive quantification methods of in vivo vesicular acetylcholine transporter using [123I]-IBVM SPECT imaging. J Cereb Blood Flow Metab. 2008;28(9):1624-34.

146. Zubal IG, Early M, Yuan O, Jennings D, Marek K, Seibyl JP. Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinson's disease patients. J Nucl Med. 2007;48(6):857-64.

147. Tamagnan GD, Brenner E, Alagille D, Staley JK, Haile C, Koren A, et al. Development of SPECT imaging agents for the norepinephrine transporters: [123I]INER. Bioorg Med Chem Lett. 2007;17(2):533-7.

148. Shang Y, Gibbs MA, Marek GJ, Stiger T, Burstein AH, Marek K, et al. Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study. J Clin Psychopharmacol. 2007;27(1):71-5.

149. Seibyl JP, Chen W, Silverman DH. 3,4-dihydroxy-6-[18f]-fluoro-L-phenylalanine positron emission tomography in patients with central motor disorders and in evaluation of brain and other tumors. Semin Nucl Med. 2007;37(6):440-50.

150. Mitsis EM, Cosgrove KP, Staley JK, Frohlich EB, Bois F, Tamagnan GD, et al. [123I]5-IA-85380 SPECT imaging of beta2-nicotinic acetylcholine receptor availability in the aging human brain. Ann N Y Acad Sci. 2007;1097:168-70.

151. Cosgrove KP, Mitsis EM, Bois F, Frohlich E, Tamagnan GD, Krantzler E, et al. 123I-5-IA-85380 SPECT imaging of nicotinic acetylcholine receptor availability in nonsmokers: effects of sex and menstrual phase. J Nucl Med. 2007;48(10):1633-40.

152. Staley JK, Sanacora G, Tamagnan G, Maciejewski PK, Malison RT, Berman RM, et al. Sex differences in diencephalon serotonin transporter availability in major depression. Biol Psychiatry. 2006;59(1):40-7.

153. Staley JK, Krishnan-Sarin S, Cosgrove KP, Krantzler E, Frohlich E, Perry E, et al. Human tobacco smokers in early abstinence have higher levels of beta2* nicotinic acetylcholine receptors than nonsmokers. J Neurosci. 2006;26(34):8707-14.

154. Malawista SE, Smith EO, Seibyl JP. Cryopreservable neutrophil surrogates: granule-poor, motile cytoplasts from polymorphonuclear leukocytes home to inflammatory lesions in vivo. Cell Motil Cytoskeleton. 2006;63(5):254-7.

155. Fong TG, Bogardus ST, Jr., Daftary A, Auerbach E, Blumenfeld H, Modur S, et al. Cerebral perfusion changes in older delirious patients using 99mTc HMPAO SPECT. J Gerontol A Biol Sci Med Sci. 2006;61(12):1294-9.

156. D'Souza DC, Gil RB, Zuzarte E, MacDougall LM, Donahue L, Ebersole JS, et al. gamma-Aminobutyric acid-serotonin interactions in healthy men: implications for network models of psychosis and dissociation. Biol Psychiatry. 2006;59(2):128-37.

157. Bennacef I, Haile CN, Schmidt A, Koren AO, Seibyl JP, Staley JK, et al. Synthesis and receptor binding studies of halogenated N,N-dialkylel-(2-phenyl-1H-indol-3-yl)glyoxylamides to visualize peripheral benzodiazepine receptors with SPECT or PET. Bioorg Med Chem. 2006;14(22):7582-91.

158. van Dyck CH, Malison RT, Jacobsen LK, Seibyl JP, Staley JK, Laruelle M, et al. Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med. 2005;46(5):745-51.

159. Staley JK, van Dyck CH, Weinzimmer D, Brenner E, Baldwin RM, Tamagnan GD, et al. 123I-5-IA-85380 SPECT measurement of nicotinic acetylcholine receptors in human brain by the constant infusion paradigm: feasibility and reproducibility. J Nucl Med. 2005;46(9):1466-72.

160. Staley JK, Gottschalk C, Petrakis IL, Gueorguieva R, O'Malley S, Baldwin R, et al. Cortical gamma-aminobutyric acid type A-benzodiazepine receptors in recovery from alcohol dependence: relationship to features of alcohol dependence and cigarette smoking. Arch Gen Psychiatry. 2005;62(8):877-88.

161. Seibyl J, Jennings D, Tabamo R, Marek K. Unique roles of SPET brain imaging in clinical and research studies. Lessons from Parkinson's disease research. Q J Nucl Med Mol Imaging. 2005;49(2):215-21.

162. Seibyl J, Jennings D, Tabamo R, Marek K. The role of neuroimaging in the early diagnosis and evaluation of Parkinson's disease. Minerva Med. 2005;96(5):353-64.

163. Ravina B, Eidelberg D, Ahlskog JE, Albin RL, Brooks DJ, Carbon M, et al. The role of radiotracer imaging in Parkinson disease. Neurology. 2005;64(2):208-15.

164. Daftary A, Gregory M, Daftary A, Seibyl JP, Saluja S. Chest radiograph as a triage tool in the imaging-based diagnosis of pulmonary embolism. AJR Am J Roentgenol. 2005;185(1):132-4.

165. Cho HS, D'Souza DC, Gueorguieva R, Perry EB, Madonick S, Karper LP, et al. Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine. Psychopharmacology (Berl). 2005;179(1):136-43.

166. Best SE, Sarrel PM, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM, et al. Striatal dopamine transporter availability with [123I]beta-CIT SPECT is unrelated to gender or menstrual cycle. Psychopharmacology (Berl). 2005;183(2):181-9.

167. van Dyck CH, Malison RT, Staley JK, Jacobsen LK, Seibyl JP, Laruelle M, et al. Central serotonin transporter availability measured with [123I]beta-CIT SPECT in relation to serotonin transporter genotype. Am J Psychiatry. 2004;161(3):525-31.

168. Seibyl J, Jennings D, Tabamo R, Marek K. Neuroimaging trials of Parkinson's disease progression. J Neurol. 2004;251 Suppl 7:vII9-13.

169. Ross SA, Seibyl JP. Research applications of selected 123I-labeled neuroreceptor SPECT imaging ligands. J Nucl Med Technol. 2004;32(4):209-14.

170. Kugaya A, Sanacora G, Staley JK, Malison RT, Bozkurt A, Khan S, et al. Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biol Psychiatry. 2004;56(7):497-502.

171. Jennings DL, Seibyl JP, Oakes D, Eberly S, Murphy J, Marek K. (123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol. 2004;61(8):1224-9.

172. Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61(7):1044-53.

173. Fujita M, Varrone A, Kim KM, Watabe H, Zoghbi SS, Seneca N, et al. Effect of scatter correction on the compartmental measurement of striatal and extrastriatal dopamine D2 receptors using [123I]epidepride SPET. Eur J Nucl Med Mol Imaging. 2004;31(5):644-54.

174. Fujita M, Southwick SM, Denucci CC, Zoghbi SS, Dillon MS, Baldwin RM, et al. Central type benzodiazepine receptors in Gulf War veterans with posttraumatic stress disorder. Biol Psychiatry. 2004;56(2):95-100.

175. Daftary A, Shulman A, Strashun AM, Gottschalk C, Zoghbi SS, Seibyl JP. Benzodiazepine receptor distribution in severe intractable tinnitus. Int Tinnitus J. 2004;10(1):17-23.

176. Seibyl JP. Imaging studies in movement disorders. Semin Nucl Med. 2003;33(2):105-13.

177. Morano GN, Seibyl JP. Technical overview of brain SPECT imaging: improving acquisition and processing of data. J Nucl Med Technol. 2003;31(4):191-5; quiz 202-3.

178. Marek K, Jennings D, Seibyl J. Single-photon emission tomography and dopamine transporter imaging in Parkinson's disease. Adv Neurol. 2003;91:183-91.

179. Marek K, Jennings D, Seibyl J. Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies. Ann Neurol. 2003;53 Suppl 3:S160-6; discussion S6-9.

180. Marek K, Jennings D, Seibyl J. Imaging the dopamine system to assess disease-modifying drugs: studies comparing dopamine agonists and levodopa. Neurology. 2003;61(6 Suppl 3):S43-8.

181. Kugaya A, Seneca NM, Snyder PJ, Williams SA, Malison RT, Baldwin RM, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology. 2003;28(2):413-20.

182. Kugaya A, Sanacora G, Verhoeff NP, Fujita M, Mason GF, Seneca NM, et al. Cerebral benzodiazepine receptors in depressed patients measured with [123I]iomazenil SPECT. Biol Psychiatry. 2003;54(8):792-9.

183. Kugaya A, Epperson CN, Zoghbi S, van Dyck CH, Hou Y, Fujita M, et al. Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. Am J Psychiatry. 2003;160(8):1522-4.

184. Fujita M, Ichise M, van Dyck CH, Zoghbi SS, Tamagnan G, Mukhin AG, et al. Quantification of nicotinic acetylcholine receptors in human brain using [123I]5-I-A-85380 SPET. Eur J Nucl Med Mol Imaging. 2003;30(12):1620-9.

185. Blumenfeld H, Westerveld M, Ostroff RB, Vanderhill SD, Freeman J, Necochea A, et al. Selective frontal, parietal, and temporal networks in generalized seizures. Neuroimage. 2003;19(4):1556-66.

186. Waxman A, Chugani H, Seibyl J. Medical imaging in neurological disorders. J Am Pharm Assoc (Wash). 2002;42(5 Suppl 1):S48-9.

187. van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM, et al. Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry. 2002;10(1):36-43.

188. van Dyck CH, Quinlan DM, Cretella LM, Staley JK, Malison RT, Baldwin RM, et al. Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder. Am J Psychiatry. 2002;159(2):309-12.

189. Marek K, Jennings D, Seibyl J. Do dopamine agonists or levodopa modify Parkinson's disease progression? Eur J Neurol. 2002;9 Suppl 3:15-22.

190. Fujita M, Seibyl JP, Vaupel DB, Tamagnan G, Early M, Zoghbi SS, et al. Whole-body biodistribution, radiation absorbed dose, and brain SPET imaging with [123i]5-i-A-85380 in healthy human subjects. Eur J Nucl Med Mol Imaging. 2002;29(2):183-90.

191. Abi-Saab W, Seibyl JP, D'Souza DC, Karper LP, Gueorgueva R, Abi-Dargham A, et al. Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms. Psychopharmacology (Berl). 2002;162(1):55-62.

192. Zoghbi SS, Tamagnan G, Fujita M, Baldwin RM, Al-Tikriti MS, Amici L, et al. Measurement of plasma metabolites of (S)-5-[123I]iodo-3-(2-azetidinylmethoxy)pyridine (5-IA-85380), a nicotinic acetylcholine receptor imaging agent, in nonhuman primates. Nucl Med Biol. 2001;28(1):91-6.

193. Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP. [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. Mov Disord. 2001;16(6):1023-32.

194. Staley JK, Krishnan-Sarin S, Zoghbi S, Tamagnan G, Fujita M, Seibyl JP, et al. Sex differences in [123I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse. 2001;41(4):275-84.

195. Soares JC, van Dyck CH, Tan P, Zoghbi SS, Garg P, Soufer R, et al. Reproducibility of in vivo brain measures of 5-HT2A receptors with PET and. Psychiatry Res. 2001;106(2):81-93.

196. Marek K, Innis R, van Dyck C, Fussell B, Early M, Eberly S, et al. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology. 2001;57(11):2089-94.

197. Goldstein S, Friedman JH, Innis R, Seibyl J, Marek K. Hemi-parkinsonism due to a midbrain arteriovenous malformation: dopamine transporter imaging. Mov Disord. 2001;16(2):350-3.

198. Fogarasi MC, Zelkowitz RS, Messana SA, Arrighi JA, Seibyl JP, Kummar S. Positron emission tomography for the evaluation of patients with colorectal cancer. Clin Colorectal Cancer. 2001;1(2):117-20.

199. Zubal IG, Avery RA, Stokking R, Studholme C, Corsi M, Dey H, et al. Ratio-images calculated from interictal positron emission tomography and single-photon emission computed tomography for quantification of the uncoupling of brain metabolism and perfusion in epilepsy. Epilepsia. 2000;41(12):1560-6.

200. Varrone A, Fujita M, Verhoeff NP, Zoghbi SS, Baldwin RM, Rajeevan N, et al. Test-retest reproducibility of extrastriatal dopamine D2 receptor imaging with [123I]epidepride SPECT in humans. J Nucl Med. 2000;41(8):1343-51.

201. van Dyck CH, Soares JC, Tan PZ, Staley JK, Baldwin RM, Amici LA, et al. Equilibrium modeling of 5-HT(2A) receptors with [18F]deuteroaltanserin and PET: feasibility of a constant infusion paradigm. Nucl Med Biol. 2000;27(8):715-22.

202. van Dyck CH, Malison RT, Seibyl JP, Laruelle M, Klumpp H, Zoghbi SS, et al. Age-related decline in central serotonin transporter availability with [(123)I]beta-CIT SPECT. Neurobiol Aging. 2000;21(4):497-501.

203. Staley JK, Tamagnan G, Baldwin RM, Fujita M, Al Tikriti MS, Eshima L, et al. SPECT imaging with the D(4) receptor antagonist L-750,667 in nonhuman primate brain. Nucl Med Biol. 2000;27(6):547-56.

204. Shulman A, Strashun AM, Seibyl JP, Daftary A, Goldstein B. Benzodiazepine receptor deficiency and tinnitus. Int Tinnitus J. 2000;6(2):98-111.

205. Marek K, Seibyl J. TechSight. Imaging. A molecular map for neurodegeneration. Science. 2000;289(5478):409-11.

206. Laruelle M, Abi-Dargham A, van Dyck C, Gil R, D'Souza DC, Krystal J, et al. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT. Biol Psychiatry. 2000;47(5):371-9.

207. Jacobsen LK, Staley JK, Zoghbi SS, Seibyl JP, Kosten TR, Innis RB, et al. Prediction of dopamine transporter binding availability by genotype: a preliminary report. Am J Psychiatry. 2000;157(10):1700-3.

208. Jacobsen LK, Staley JK, Malison RT, Zoghbi SS, Seibyl JP, Kosten TR, et al. Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients. Am J Psychiatry. 2000;157(7):1134-40.

209. Fujita M, Verhoeff NP, Varrone A, Zoghbi SS, Baldwin RM, Jatlow PA, et al. Imaging extrastriatal dopamine D(2) receptor occupancy by endogenous dopamine in healthy humans. Eur J Pharmacol. 2000;387(2):179-88.

210. Fujita M, Tamagnan G, Zoghbi SS, Al-Tikriti MS, Baldwin RM, Seibyl JP, et al. Measurement of alpha4beta2 nicotinic acetylcholine receptors with [123I]5-I-A-85380 SPECT. J Nucl Med. 2000;41(9):1552-60.

211. Castner SA, al-Tikriti MS, Baldwin RM, Seibyl JP, Innis RB, Goldman-Rakic PS. Behavioral changes and [123I]IBZM equilibrium SPECT measurement of amphetamine-induced dopamine release in rhesus monkeys exposed to subchronic amphetamine. Neuropsychopharmacology. 2000;22(1):4-13.

212. Avery RA, Zubal IG, Stokking R, Studholme C, Corsi M, Seibyl JP, et al. Decreased cerebral blood flow during seizures with ictal SPECT injections. Epilepsy Res. 2000;40(1):53-61.

213. Avery RA, Spencer SS, Studholme C, Stokking R, Morano G, Corsi M, et al. Reproducibility of serial peri-ictal single-photon emission tomography difference images in epilepsy patients undergoing surgical resection. Eur J Nucl Med. 2000;27(1):50-5.

214. Anand A, Verhoeff P, Seneca N, Zoghbi SS, Seibyl JP, Charney DS, et al. Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am J Psychiatry. 2000;157(7):1108-14.

215. Zubal IG, Spanaki MV, MacMullan J, Corsi M, Seibyl JP, Spencer SS. Influence of technetium-99m-hexamethylpropylene amine oxime injection time on single-photon emission tomography perfusion changes in epilepsy. Eur J Nucl Med. 1999;26(1):12-7.

216. Verhoeff NP, Soares JC, D'Souza CD, Gil R, Degen K, Abi-Dargham A, et al. [123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia. Psychiatry Res. 1999;91(3):163-73.

217. Verhoeff NP, Petroff OA, Hyder F, Zoghbi SS, Fujita M, Rajeevan N, et al. Effects of vigabatrin on the GABAergic system as determined by [123I]iomazenil SPECT and GABA MRS. Epilepsia. 1999;40(10):1433-8.

218. Spanaki MV, Spencer SS, Corsi M, MacMullan J, Seibyl J, Zubal IG. Sensitivity and specificity of quantitative difference SPECT analysis in seizure localization. J Nucl Med. 1999;40(5):730-6.

219. Spanaki MV, Spencer SS, Corsi M, MacMullan J, Seibyl J, Zubal IG. The role of quantitative ictal SPECT analysis in the evaluation of nonepileptic seizures. J Neuroimaging. 1999;9(4):210-6.

220. Seibyl JP. Single-photon emission computed tomography of the dopamine transporter in parkinsonism. J Neuroimaging. 1999;9(4):223-8.

221. Innis RB, Marek KL, Sheff K, Zoghbi S, Castronuovo J, Feigin A, et al. Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT. Mov Disord. 1999;14(3):436-42.

222. Ichise M, Fujita M, Seibyl JP, Verhoeff NP, Baldwin RM, Zoghbi SS, et al. Graphical analysis and simplified quantification of striatal and extrastriatal dopamine D2 receptor binding with [123I]epidepride SPECT. J Nucl Med. 1999;40(11):1902-12.

223. Fujita M, Woods SW, Verhoeff NP, Abi-Dargham A, Baldwin RM, Zoghbi SS, et al. Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans. Eur J Pharmacol. 1999;368(2-3):161-72.

224. Fujita M, Seibyl JP, Verhoeff NP, Ichise M, Baldwin RM, Zoghbi SS, et al. Kinetic and equilibrium analyses of [(123)I]epidepride binding to striatal and extrastriatal dopamine D(2) receptors. Synapse. 1999;34(4):290-304.

225. Bremner JD, Baldwin R, Horti A, Staib LH, Ng CK, Tan PZ, et al. Quantitation of benzodiazepine receptor binding with PET [11C]iomazenil and SPECT [123I]iomazenil: preliminary results of a direct comparison in healthy human subjects. Psychiatry Res. 1999;91(2):79-91.

226. Avery RA, Spencer SS, Spanaki MV, Corsi M, Seibyl JP, Zubal IG. Effect of injection time on postictal SPET perfusion changes in medically refractory epilepsy. Eur J Nucl Med. 1999;26(8):830-6.

227. Abi-Dargham A, Laruelle M, Krystal J, D'Souza C, Zoghbi S, Baldwin RM, et al. No evidence of altered in vivo benzodiazepine receptor binding in schizophrenia. Neuropsychopharmacology. 1999;20(6):650-61.

228. van Dyck CH, Gelernter J, MacAvoy MG, Avery RA, Criden M, Okereke O, et al. Absence of an apolipoprotein E epsilon4 allele is associated with increased parietal regional cerebral blood flow asymmetry in Alzheimer disease. Arch Neurol. 1998;55(11):1460-6.

229. Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM, Charney DS, et al. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med. 1998;39(9):1500-8.

230. Rajeevan N, Zubal IG, Ramsby SQ, Zoghbi SS, Seibyl J, Innis RB. Significance of nonuniform attenuation correction in quantitative brain SPECT imaging. J Nucl Med. 1998;39(10):1719-26.

231. Malison RT, Price LH, Berman R, van Dyck CH, Pelton GH, Carpenter L, et al. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry. 1998;44(11):1090-8.

232. Malison RT, McCance E, Carpenter LL, Baldwin RM, Seibyl JP, Price LH, et al. [123I]beta-CIT SPECT imaging of dopamine transporter availability after mazindol administration in human cocaine addicts. Psychopharmacology (Berl). 1998;137(4):321-5.

233. Malison RT, Best SE, van Dyck CH, McCance EF, Wallace EA, Laruelle M, et al. Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I] beta-CIT SPECT. Am J Psychiatry. 1998;155(6):832-4.

234. Kosten TR, Cheeves C, Palumbo J, Seibyl JP, Price LH, Woods SW. Regional cerebral blood flow during acute and chronic abstinence from combined cocaine-alcohol abuse. Drug Alcohol Depend. 1998;50(3):187-95.

235. Dey HM, Daley L, Ng CK, Zubal G, Freedman G, Seibyl JP. Detection of Pulmonary Malignancy with a Coincidence Capable Gamma Camera. Preliminary Comparison to Traditional PET. Clin Positron Imaging. 1998;1(4):259.

236. Bowers MB, Jr., Malison RT, Seibyl JP, Kosten TR. Plasma homovanillic acid and the dopamine transporter during cocaine withdrawal. Biol Psychiatry. 1998;43(4):278-81.

237. Boiselle PM, Reddy SS, Villas PA, Liu A, Seibyl JP. Pulmonary embolus in pregnant patients: survey of ventilation-perfusion imaging policies and practices. Radiology. 1998;207(1):201-6.

238. Seibyl JP, Marek K, Sheff K, Baldwin RM, Zoghbi S, Zea-Ponce Y, et al. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. J Nucl Med. 1997;38(9):1453-9.

239. Seibyl JP. Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia. J Psychopharmacol. 1997;11(2):188-9.

240. Laruelle M, D'Souza CD, Baldwin RM, Abi-Dargham A, Kanes SJ, Fingado CL, et al. Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology. 1997;17(3):162-74.

241. van Dyck CH, Seibyl JP, Stubbs JB, Zoghbi S, Wisniewski G, Baldwin RM, et al. Human biodistribution and dosimetry of the SPECT D2 dopamine receptor radioligand [123I]IBF. Nucl Med Biol. 1996;23(1):9-16.

242. Seibyl JP, Zea-Ponce Y, Brenner L, Baldwin RM, Krystal JH, Offord SJ, et al. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796. J Nucl Med. 1996;37(1):11-5.

243. Seibyl JP, Marek K, Innis RB. Images in neuroscience. Neuroimaging, XII. SPECT imaging of dopamine nerve terminals. Am J Psychiatry. 1996;153(9):1131.

244. Seibyl JP, Laruelle M, van Dyck CH, Wallace E, Baldwin RM, Zoghbi S, et al. Reproducibility of iodine-123-beta-CIT SPECT brain measurement of dopamine transporters. J Nucl Med. 1996;37(2):222-8.

245. Marek KL, Seibyl JP, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Fussell B, et al. [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology. 1996;46(1):231-7.

246. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A. 1996;93(17):9235-40.

247. Zubal IG, Spencer SS, Imam K, Seibyl J, Smith EO, Wisniewski G, et al. Difference images calculated from ictal and interictal technetium-99m-HMPAO SPECT scans of epilepsy. J Nucl Med. 1995;36(4):684-9.

248. van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Wallace E, Zoghbi SS, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CITSPECT. J Nucl Med. 1995;36(7):1175-81.

249. Seibyl JP, Marek KL, Quinlan D, Sheff K, Zoghbi S, Zea-Ponce Y, et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol. 1995;38(4):589-98.

250. Malison RT, McDougle CJ, van Dyck CH, Scahill L, Baldwin RM, Seibyl JP, et al. [123I]beta-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. Am J Psychiatry. 1995;152(9):1359-61.

251. Malison RT, Best SE, Wallace EA, McCance E, Laruelle M, Zoghbi SS, et al. Euphorigenic doses of cocaine reduce [123I]beta-CIT SPECT measures of dopamine transporter availability in human cocaine addicts. Psychopharmacology (Berl). 1995;122(4):358-62.

252. Krystal JH, Woods SW, Kosten TR, Rosen MI, Seibyl JP, van Dyck CC, et al. Opiate dependence and withdrawal: preliminary assessment using single photon emission computerized tomography (SPECT). Am J Drug Alcohol Abuse. 1995;21(1):47-63.

253. Bremner JD, Randall P, Scott TM, Bronen RA, Seibyl JP, Southwick SM, et al. MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. Am J Psychiatry. 1995;152(7):973-81.

254. Baldwin RM, Zea-Ponce Y, al-Tikriti MS, Zoghbi SS, Seibyl JP, Charney DS, et al. Regional brain uptake and pharmacokinetics of [123I]N-omega-fluoroalkyl-2 beta-carboxy-3 beta-(4-iodophenyl)nortropane esters in baboons. Nucl Med Biol. 1995;22(2):211-9.

255. al-Tikriti MS, Zea-Ponce Y, Baldwin RM, Zoghbi SS, Laruelle M, Seibyl JP, et al. Characterization of the dopamine transporter in nonhuman primate brain: homogenate binding, whole body imaging, and ex vivo autoradiography using [125I] and [123I]IPCIT. Nucl Med Biol. 1995;22(5):649-58.

256. Seibyl JP, Wallace E, Smith EO, Stabin M, Baldwin RM, Zoghbi S, et al. Whole-body biodistribution, radiation absorbed dose and brain SPECT imaging with iodine-123-beta-CIT in healthy human subjects. J Nucl Med. 1994;35(5):764-70.

257. Laruelle M, Wallace E, Seibyl JP, Baldwin RM, Zea-Ponce Y, Zoghbi SS, et al. Graphical, kinetic, and equilibrium analyses of in vivo [123I] beta-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab. 1994;14(6):982-94.

258. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51(3):199-214.

259. Docherty NM, Evans IM, Sledge WH, Seibyl JP, Krystal JH. Affective reactivity of language in schizophrenia. J Nerv Ment Dis. 1994;182(2):98-102.

260. Dey HM, Seibyl JP, Stubbs JB, Zoghbi SS, Baldwin RM, Smith EO, et al. Human biodistribution and dosimetry of the SPECT benzodiazepine receptor radioligand iodine-123-iomazenil. J Nucl Med. 1994;35(3):399-404.

261. Baldwin RM, Zea-Ponce Y, Zoghbi SS, al-Tikriti MS, Seibyl JP, Sybirska EH, et al. Pharmacokinetics of the three radioiodinated dopamine D2 receptor ligands [123I]IBF, [123I]epidepride and [123I]2'-ISP in nonhuman primates. Nucl Med Biol. 1994;21(7):969-76.

262. Abi-Dargham A, Laruelle M, Seibyl J, Rattner Z, Baldwin RM, Zoghbi SS, et al. SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil: kinetic and equilibrium paradigms. J Nucl Med. 1994;35(2):228-38.

263. Sybirska E, Seibyl JP, Bremner JD, Baldwin RM, al-Tikriti MS, Bradberry C, et al. [123I]iomazenil SPECT imaging demonstrates significant benzodiazepine receptor reserve in human and nonhuman primate brain. Neuropharmacology. 1993;32(7):671-80.

264. Seibyl JP, Satel SL, Anthony D, Southwick SM, Krystal JH, Charney DS. Effects of cocaine on hospital course in schizophrenia. J Nerv Ment Dis. 1993;181(1):31-7.

265. Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am J Psychiatry. 1993;150(9):1408-10.

266. Krystal JH, Seibyl JP, Price LH, Woods SW, Heninger GR, Aghajanian GK, et al. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia. Arch Gen Psychiatry. 1993;50(8):624-35.

267. Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallace E, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci U S A. 1993;90(24):11965-9.

268. Zoghbi SS, Baldwin RM, Seibyl JP, al-Tikriti MS, Zea-Ponce Y, Laruelle M, et al. Pharmacokinetics of the SPECT benzodiazepine receptor radioligand [123I]iomazenil in human and non-human primates. Int J Rad Appl Instrum B. 1992;19(8):881-8.

269. Woods SW, Seibyl JP, Goddard AW, Dey HM, Zoghbi SS, Germine M, et al. Dynamic SPECT imaging after injection of the benzodiazepine receptor ligand [123I]iomazenil in healthy human subjects. Psychiatry Res. 1992;45(2):67-77.

270. Seibyl JP, Woods SW, Zoghbi SS, Baldwin RM, Dey HM, Goddard AW, et al. Dynamic SPECT imaging of dopamine D2 receptors in human subjects with iodine-123-IBZM. J Nucl Med. 1992;33(11):1964-71.

271. Seibyl JP, Brenner L, Krystal JH, Johnson R, Charney DS. Mazindol and cocaine addiction in schizophrenia. Biol Psychiatry. 1992;31(11):1179-81.

272. Karper LP, Seibyl JP, Krystal JH. Valproate management of psychosis in a patient with carbamazepine-induced hyponatremia. J Clin Psychopharmacol. 1992;12(2):137-9.

273. Karper LP, Salloway SP, Seibyl JP, Krystal JH. Prolonged postictal encephalopathy in two patients with clozapine-induced seizures. J Neuropsychiatry Clin Neurosci. 1992;4(4):454-7.

274. Johnson EW, de Lanerolle NC, Kim JH, Sundaresan S, Spencer DD, Mattson RH, et al. "Central" and "peripheral" benzodiazepine receptors: opposite changes in human epileptogenic tissue. Neurology. 1992;42(4):811-5.

275. Innis RB, Malison RT, al-Tikriti M, Hoffer PB, Sybirska EH, Seibyl JP, et al. Amphetamine-stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates. Synapse. 1992;10(3):177-84.

276. Seibyl JP, Krystal JH, Price LH, Woods SW, D'Amico C, Heninger GR, et al. Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects. Psychiatry Res. 1991;38(3):227-36.

277. Satel SL, Seibyl JP, Charney DS. Prolonged cocaine psychosis implies underlying major psychopathology. J Clin Psychiatry. 1991;52(8):349-50.

278. Satel SL, Seibyl JP. DSM-III-R criteria for cocaine disorders. Am J Psychiatry. 1991;148(8):1088.

279. Innis RB, al-Tikriti MS, Zoghbi SS, Baldwin RM, Sybirska EH, Laruelle MA, et al. SPECT imaging of the benzodiazepine receptor: feasibility of in vivo potency measurements from stepwise displacement curves. J Nucl Med. 1991;32(9):1754-61.

280. Innis R, Zoghbi S, Johnson E, Woods S, al-Tikriti M, Baldwin R, et al. SPECT imaging of the benzodiazepine receptor in non-human primate brain with [123I]Ro 16-0154. Eur J Pharmacol. 1991;193(2):249-52.

281. Seibyl JP, Krystal JH, Charney DS. Marijuana (cannabis) use is anecdotally said to precipitate anxiety symptoms in patients with panic disorder. Is there any research evidence to support this? Also, can marijuana use precipitate or expose paranoia in patients with an underlying bipolar disorder? J Clin Psychopharmacol. 1990;10(1):78.

282. Giakas WJ, Seibyl JP, Mazure CM. Valproate in the treatment of temper outbursts. J Clin Psychiatry. 1990;51(12):525.

283. Seibyl JP, Krystal JH, Price LH, Charney DS. Use of yohimbine to counteract nortriptyline-induced orthostatic hypotension. J Clin Psychopharmacol. 1989;9(1):67-8.